Moderna Remains 'Cautious' on Guidance, CEO Bancel Says

The video discusses the company's Q1 performance and decision to maintain current guidance due to uncertainties in transitioning from pandemic to endemic. It highlights a $5 billion sales target for 2023, excluding potential contracts in the US, Japan, Europe, and other regions. The speaker emphasizes ongoing discussions with pharmacy and hospital chains, and government agencies. Despite public perception that COVID is over, governments are preparing for potential fall outbreaks, similar to flu season. The video also addresses the risk of new, more severe variants emerging.

Why is the company not changing its guidance despite positive Q1 results?

• They are overly confident about future sales.

• They want to be cautious due to the transition from pandemic to endemic.

• They have already achieved their annual sales target.

• They are waiting for new contracts to be finalized.

What is the company's sales target for 2023 based on existing contracts?

• $3 billion

• $5 billion

• $10 billion

• $7 billion

Which regions are mentioned as not yet included in the company's sales numbers?

• Europe and Southeast Asia

• Both B and C

• Africa and Australia

• US and Japan

What is the general public's attitude towards COVID-19 in New York, according to the speaker?

• They are preparing for a new wave.

• They are indifferent to it.

• They are very concerned about it.

• They believe COVID-19 is over.

Why is it important for governments to prepare for COVID-19 in the fall?

• Because the flu season is not a concern.

• Because the public demands it.

• Because new variants may emerge that are more severe.

• Because COVID-19 is less severe than the flu.